The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

The results of the DeFi trial of nirogacestat in 142 adults with progressing desmoid ... coming in the wake of a $225 million private placement and the GSK alliance, which together have helped ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...